Where ESMA has identified that an OTC derivative product is standardised and suitable for clearing but no CCP is willing to clear that product, ESMA should investigate the reason for this.
Recital 18, Regulation (EU) No 648/2012 of the European Parliament and of the Council of 4 July 2012…
In forcesince 4 Jul 2012